ArticleJournal of epidemiology and global health2025
Disease Burden of 30 Cancer Groups in Taiwan from 2000 to 2021.
Article in Journal of epidemiology and global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MAD2L1 overexpression promotes breast cancer progression and confers resistance to paclitaxel via proteasomal stabilization.Oncology letters · 2026Article
- Integrating CT-Based Radiomics Analysis With Serum CEA Level to Predict Neoadjuvant Chemoradiotherapy Response in Colorectal Cancer.The Kaohsiung journal of medical sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAssessment of the morbidity and mortality burden of cancers and their evolving trends is crucial for making informed policy decisions and effective resource allocation. We aimed to examine the burden of cancer in Taiwan from 2000 to 2021 using a national population-based database.
methodsLinking data from the Taiwan Cancer Registry and National Death Registry, we calculated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) for 30 specific cancer groups. Our methodology aligns with the Global Burden of Disease Study.
resultsIn Taiwan, from 2000 to 2021, the age-standardized cancer mortality rate decreased by 13.8%, while the prevalence rate increased by 80.5%. In 2021, the age-standardized DALYs for total cancer were 3784.2 per 100,000 population. In 2021, in Taiwan, lung, liver, and colorectal cancers were the leading contributors to cancer-related DALYs for men, whereas breast, lung, and colorectal cancers were predominant for women. Life expectancy decomposition analysis revealed distinct patterns by sex, with significant gains for specific cancers from 2000 to 2021: cervical, stomach, and liver cancers in women (0.20, 0.13, and 0.12 years, respectively) and liver, lung, and stomach cancers in men (0.37, 0.17, and 0.17 years, respectively).
conclusionOur finding of declining cancer DALY rates in Taiwan over the past two decades may reflect improvements in cancer control, particularly the significant decrease in liver and lung cancer burden. However, the rising burden of breast cancer and the sustained impact of colorectal and oral cancers warrant targeted attention in health policies, resource allocation, and research to reduce healthcare costs and improve quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.